The use of sulfanilamide to prevent hemolytic streptococcus infections and recrudescences of acute rheumatism in persons known to be subject to rheumatic fever has given encouraging results. The observations by Thomas and her collaborators1 working with adults in Baltimore, and observations on children in New York2 indicated that a level of sulfanilamide in the blood of about 40 micrograms per cubic centimeter maintained throughout the school year protected against streptococcic pharyngitis and rheumatic recrudescences. One factor that it was impossible to control in the New York study was the increasing age of the group. Between 1936 and 1939 many of the children passed puberty, and, as is well recognized, rheumatic subjects tend to have fewer recrudescences in adolescence than during childhood. It was therefore possible to regard the increasing age of our patients as largely contributory to the decreased incidence of rheumatic fever.
One way of determining whether
Coburn AF, Moore LV. A FOLLOW-UP REPORT ON RHEUMATIC SUBJECTS TREATED WITH SULFANILAMIDE. JAMA. 1941;117(3):176. doi:10.1001/jama.1941.72820290004005b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: